Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.

Friberg LE, Vermeulen AM, Petersson KJ, Karlsson MO.

Clin Pharmacol Ther. 2009 Apr;85(4):409-17. doi: 10.1038/clpt.2008.234. Epub 2008 Dec 24.

PMID:
19109590
2.

Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.

Ma G, Friberg LE, Movin-Osswald G, Karlsson MO.

Br J Clin Pharmacol. 2010 Dec;70(6):815-24. doi: 10.1111/j.1365-2125.2010.03758.x.

3.

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.

Berwaerts J, Cleton A, Rossenu S, Talluri K, Remmerie B, Janssens L, Boom S, Kramer M, Eerdekens M.

J Psychopharmacol. 2010 Jul;24(7):1011-8. doi: 10.1177/0269881109106914. Epub 2009 Oct 13.

PMID:
19825908
4.

Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

Kozielska M, Johnson M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2012 Jul;29(7):1932-48. doi: 10.1007/s11095-012-0722-8. Epub 2012 Mar 22.

5.

A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.

Marchese G, Pittau B, Casu G, Peddio G, Spada GP, Pira M, Deriu A, Portesani F, Pisu C, Lazzari P, Pani L.

Eur Psychiatry. 2010 Mar;25(2):92-100. doi: 10.1016/j.eurpsy.2009.05.008. Epub 2009 Jul 28.

PMID:
19640686
6.

Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.

Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ.

J Clin Psychopharmacol. 2007 Feb;27(1):52-7.

PMID:
17224713
7.

Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.

Duval F, Guillon MS, Mokrani MC, Crocq MA, Garcia Duarte F.

Psychoneuroendocrinology. 2008 Feb;33(2):255-9. Epub 2007 Nov 28.

PMID:
18053652
8.

Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers.

Lee DY, Lee KU, Kwon JS, Jang IJ, Cho MJ, Shin SG, Woo JI.

Psychopharmacology (Berl). 1999 Jun;144(3):272-8.

PMID:
10435394
9.

Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.

Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Kaneko S.

J Clin Psychopharmacol. 2005 Dec;25(6):527-32.

PMID:
16282832
10.

A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.

Taneja A, Vermeulen A, Huntjens DRH, Danhof M, De Lange ECM, Proost JH.

Eur J Pharmacol. 2016 Oct 15;789:202-214. doi: 10.1016/j.ejphar.2016.07.005. Epub 2016 Jul 6.

PMID:
27395799
11.

Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.

Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH, He L.

J Psychopharmacol. 2007 Nov;21(8):837-42. Epub 2007 Aug 22.

PMID:
17715206
12.

Paliperidone: quo vadis?

Citrome L.

Int J Clin Pract. 2007 Apr;61(4):653-62. Epub 2007 Mar 2. Review.

PMID:
17343660
13.

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.

Pani L, Marchese G.

Expert Opin Drug Deliv. 2009 Mar;6(3):319-31. doi: 10.1517/17425240902780158. Review.

PMID:
19317589
14.

Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.

LLerena A, Berecz R, Dorado P, de la Garza CS, Norberto MJ, Cáceres M, Gutiérrez JR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5;783(1):213-9.

PMID:
12450541
15.

Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration.

Bagli M, Süverkrüp R, Quadflieg R, Höflich G, Kasper S, Möller HJ, Langer M, Barlage U, Rao ML.

J Pharmacol Exp Ther. 1999 Nov;291(2):547-54.

16.

Paliperidone for schizophrenia.

Dolder C, Nelson M, Deyo Z.

Am J Health Syst Pharm. 2008 Mar 1;65(5):403-13. doi: 10.2146/ajhp070261. Review.

PMID:
18281731
17.

No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects.

Thyssen A, Cleton A, Talluri K, Leempoels J, Janssens L, Boom S, Eerdekens M.

Hum Psychopharmacol. 2009 Oct;24(7):532-9. doi: 10.1002/hup.1049.

PMID:
19693799
19.

The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.

Spina E, Cavallaro R.

Expert Opin Drug Saf. 2007 Nov;6(6):651-62. Review.

PMID:
17967154
20.

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH.

Clin Pharmacol Ther. 1993 Sep;54(3):257-68.

PMID:
7690693

Supplemental Content

Support Center